Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;83(2):e153-e154.
doi: 10.1016/j.jaad.2020.05.012. Epub 2020 May 8.

Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa

Janyla A Seltzer  1 , Chidubem A V Okeke  1 , Jessica D Perry  1 , William D Shipman  2 , Ginette A Okoye  3 , Angel S Byrd  3
Affiliations
Comment

Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa

Janyla A Seltzer et al. J Am Acad Dermatol. 2020 Aug.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Overlap of comorbidities associated with hidradenitis suppurativa and risk factors of severe COVID-19 infection.
See this image and copyright information in PMC

Comment in

Comment on

  • COVID-19 and racial disparities.
    Shah M, Sachdeva M, Dodiuk-Gad RP. Shah M, et al. J Am Acad Dermatol. 2020 Jul;83(1):e35. doi: 10.1016/j.jaad.2020.04.046. Epub 2020 Apr 17. J Am Acad Dermatol. 2020. PMID: 32305444 Free PMC article. No abstract available.

References

    1. Shah M., Sachdeva M., Dodiuk-Gad R.P. COVID-19 and racial disparities. J Am Acad Dermatol. 2020;83(1):e35. - PMC - PubMed
    1. Vlassova N., Kuhn D., Okoye G.A. Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol. 2015;95(8):990–991. - PubMed
    1. Tzellos T., Zouboulis C.C. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb) 2020;10(1):63–71. - PMC - PubMed
    1. Zheng Z., Peng F., Xu B., et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020 doi: 10.1016/j.jinf.2020.04.021. [e-pub ahead of print] - DOI - PMC - PubMed
    1. Price K.N., Frew J.W., Hsiao J.L., Shi V.Y. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82(5):e173–e175. - PMC - PubMed